Business
Aussie cannabis players blaze a trail in Europe – The Australian Financial Review
ASX-listed MGC Pharma has floated in London while Little Green Pharma has placed $22 million of shares, as the high-potential European market beckons.
Australia is so set up to have a really great crack at being the dominant player in Europe, said LGP founder and CEO Fleta Solomon.
She said the Australian advantage was that the Therapeutic Goods Associations good manufacturing practice (GMP) standards were recognised as complying with the European Unions high bar, whereas producers in other countries had to negotiate EU clearance.
The biggest companies in the world dont have EU GMP. Thats what is so exciting for us as Australian players. Our GMP…
-
Business8 hours agoDicker Data rides the AI trend to double digit growth
-
Business12 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business16 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business11 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy